Fundraising Fox
Egle Therapeutics
Founded 2020 · 52 employees on LinkedIn · 4 known investors
Find your way into Egle Therapeutics
Sign up to find every way you can get introduced to Egle Therapeutics
- Your email: who you already know at Egle Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Egle Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Egle Therapeutics develops targeted immunotherapy drugs by leveraging regulatory T cell (Treg) biology to treat autoimmune diseases and cancer. The company creates drug candidates that selectively modulate Tregs to inhibit them in tumors or expand them in inflamed tissues.
Founders & leadership
Board
Investors · 4
How we know: the company's own site · a partner's Signal profile · Not right? Tell us
How we know: a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us
Founder mafia
2 people who came through Egle Therapeutics went on to found or lead other companies.
Frequently asked questions
- What does Egle Therapeutics do?
- Egle Therapeutics develops targeted immunotherapy drugs by leveraging regulatory T cell (Treg) biology to treat autoimmune diseases and cancer. The company creates drug candidates that selectively modulate Tregs to inhibit them in tumors or expand them in inflamed tissues.
- Who are Egle Therapeutics's investors?
- Egle Therapeutics's investors include EQT Life Sciences, Fund+, JDRF T1D Fund, Bioqube Ventures.